跳至主要内容
临床试验/NCT06282549
NCT06282549进行中(未招募)不适用

A Prospective Long-term Cohort Study to Identify the Predictive Model of Cardiocerebrovascular Risk Factors in Elderly Patients with More Than Three Antihypertensive Agents in Patients with Essential Hypertension in Korea

Yuhan Corporation5 个研究点 分布在 1 个国家目标入组 1,219 人开始时间: 2022年6月8日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
1,219
试验地点
5
主要终点
Percentage of MACCE(Major Adverse Cardiovascular and Cerebrovascular Events)

研究概览

简要总结

This study is to develop a predictive model for cardiocerebrovascular risk factors in elderly patients with essential hypertension with Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination.

详细描述

This is a phase IV, open-label, prospective, long-term cohort, observational study to identify the predictive model of cardiocerebrovascular risk factors in elderly patients with more than three antihypertensive agents in patients with essential hypertension in Korea.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
65 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • A patient over 65-year-old with essential hypertension
  • A patient with essential hypertension who require treatment with 3 or more antihypertensive medication, as determined by investigator's decision
  • A patient with no MACCE within 6 months prior to the enrollment
  • A patient who voluntarily signed the informed consent form

排除标准

  • A patient who participates in clinical trial
  • A patient who are contraindicated for the Truset tablet according to the label.
  • A patient who is unable to complete the study judged by the investigator.

结局指标

主要结局

Percentage of MACCE(Major Adverse Cardiovascular and Cerebrovascular Events)

时间窗: 12, 24 and 36months

Percentage of MACCE(Major Adverse Cardiovascular and Cerebrovascular Events) after treatment at 12, 24 and 36months if applicable

次要结局

  • Percentage of MACCE(Major Adverse Cardiovascular and Cerebrovascular Events) in patients with asymptomatic target organ damage(12, 24 and 36months)
  • Mean Systolic Blood Pressure (MSBP)/ Diastolic Blood Pressure (MDBP)(12, 24 and 36months)
  • Patients Achieving the treatment goal in Mean Systolic Blood Pressure (MSBP)(36months)
  • Percentage of patients who terminated the treatment(36months)

研究者

发起方
Yuhan Corporation
申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验